MGC Pharmaceuticals Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of MGC Pharmaceuticals Limited generated cash of -$11,985,175, which is more than the previous year. Cash used in financing activities reached the amount of $9,732,454 last year. Net change in cash is therefore -$1,646,526.
Cash Flow
| 2012 | -379.44K | 0 | -175.61K |
|---|---|---|---|
| 2016 | -3.22M | -650.94K | 11.33M |
| 2018 | -5.88M | -340.57K | 4.70M |
| 2020 | -9.95M | -969.88K | 10.46M |
| 2021 | -11.98M | -1.49M | 17.05M |
| 2023 | -11.98M | 606.19K | 9.73M |
MXC.L Cash Flow Statement (2012 – 2022)
| 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 1.88M | 1.87M | 2.35M | 11.36M | 436.98K | 1.07M |
Operating activities | ||||||
Net income | -20.82M | -15.86M | -19.36M | -8.24M | -6.15M | -290.88K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 751.93K | 491.40K | 481.13K | 328.11K | 1.77M | 0 |
Stock-based compensation expense | 2.65M | 1.64M | 854.91K | 1.07M | 0 | 0 |
| Deferred income tax benefit | 2.65M | 1.64M | 854.91K | 1.07M | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 1.40M | -2.22M | 271.91K | -319.07K | -393.75K | 0 |
Inventories | 475.30K | -470.20K | -263.43K | -204.44K | -157.03K | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -11.98M | -11.98M | -9.95M | -5.88M | -3.22M | -379.44K |
Investing activities | ||||||
Purchases Of Investments | 0 | 70.42K | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -189.87K | -3.32M | -962.09K | -459.44K | -247.92K | 0 |
Acquisitions Net | 0 | -373.24K | -13.25K | 0 | 142.57K | 0 |
Cash generated by investing activities | 606.19K | -1.49M | -969.88K | -340.57K | -650.94K | 0 |
Financing activities | ||||||
Common Stock Issued | 3.08M | 12.75M | 11.43M | 5.01M | 11.12M | 250K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -317.83K | -1.20M | -787.67K | -316.84K | -597.18K | 0 |
Repayments of term debt | 0 | -255.99K | 0 | 0 | 0 | -37.83K |
Cash used in financing activities | 9.73M | 17.05M | 10.46M | 4.70M | 11.33M | -175.61K |
Net Change In Cash | -1.64M | 3.55M | -480.71K | -1.50M | 7.45M | -555.05K |
Cash at end of period | 239.82K | 5.43M | 1.87M | 9.85M | 7.89M | 515.82K |
| Data source | Data source | Data source | Data source | Data source | Data source |